Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC-520 + tenofovir disoproxil + pegylated interferon alpha 2a
- Development stage
- Discontinued
- Lead developer
- Arrowhead Pharmaceuticals
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
ARC-520 + tenofovir disoproxil + pegylated interferon alpha 2a is a combination regimen investigated for the treatment of chronic hepatitis B virus (HBV) infection. ARC-520 is an RNA interference (RNAi) therapeutic designed to target and degrade hepatitis B viral mRNA transcripts produced from covalently closed circular DNA (cccDNA), thereby reducing the expression of viral proteins such as HBsAg and core-related antigens. Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor, which blocks the enzyme needed for viral DNA replication. Pegylated interferon alpha 2a is an immunomodulatory cytokine that stimulates antiviral immune responses and can promote seroclearance of viral antigens. The combination aims to reduce viral antigens, suppress viral replication, and enhance host immune control to increase the rates of functional cure (seroclearance of HBsAg). This regimen has been studied in multi-center, open-label clinical trials for both HBeAg-positive and HBeAg-negative chronic HBV patients[1][5][6][3][2].
- Other names
- TDF + PEG-IFN alpha 2a + ARC-520
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on ARC-520 + tenofovir disoproxil + pegylated interferon alpha 2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC-520 + tenofovir disoproxil + pegylated interferon alpha 2a.